
IGC Pharma Expands CALMA Phase 2 Trial to Island Health’s Royal Jubilee Hospital in Canada
POTOMAC, MD, September 02, 2025 / IGC Pharma, Inc. (NYSE American: IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment for agitation in